TRG-100
for IC/BPS
12%
women in the USA
Interstitial Cystitis /
Bladder Pain Syndrome (IC/BPS)
TRG-120
for Overactive Bladder
GM $3.5B
by 2022
Overactive Bladder
TRG-140
for Bladder Cancer
GM 1.14B
by 2025
BCG refractory Non-muscle Invasive Bladder Cancer (NMIBC)
TRG-100
for IC/BPS
TRG-100 is a novel, effective, and safe therapy for interstitial cystitis/ bladder pain syndrome, alleviating pain and urinary urgency as well as enhance patient compliance and improve quality of life with minimal systemic side effects.
Key benefits
TRG-100 is highly effective with most patients experiencing more than 50% reduction in pain and alleviates urination episodes frequency throughout the day
TRG-120
for Overactive Bladder
TRG-120 is a novel, effective, and safe therapy for chronic Overactive Bladder, designed to reduce urinary urgency as well as enhance patient compliance and improve quality of life
TRG-120 Reduce Urination Frequency in OAB
TRG-140
for Bladder Cancer
TRG-140 is a treatment of patients with non-muscle invasive bladder cancer who are not responding to current standard of care (BCG).
Key benefits
Gemcitabine therapy has superior clinical impact on recurrence and progression-free survival than mitomycin as well as BCG in individuals with high-risk non muscle invasive bladder cancer (NMIBC) diseases who have previously failed BCG.
1Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review. Investig Clin Urol. 2021 Nov;62(6):623-630.
Fill out the form bellow